The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis

Table 1

Univariate analysis of factors associated with pCR.

Characteristic		Non-pCR	pCR	Χ^2
Age (year)	≤40	15	2	0.013	0.910
	>40	89	13
Histological type	Invasive ductal	99	15	0.753	0.386
	Invasive papillary	5	0
Histological grade	2	79	9	1.734	0.188
	3	25	6
ER status	Negative	54	6	0.745	0.388
	Positive	50	9
PR status	Negative	71	6	4.587	0.032
	Positive	33	9
Ki67	≤30%	70	6	4.2	0.040
	>30%	34	9
Primary tumor size preoperation	cT1	0	1	15.748	0.001
	cT2	27	9
	cT3	42	4
	cT4	35	1
Regional lymph node preoperation	cN0	3	0	1.38	0.710
	cN1	23	5
	cN2	28	3
	cN3	50	7
Clinical stage preoperation	IIA	2	0	10.368	0.035
	IIB	5	4
	IIIA	35	4
	IIIB	11	0
	IIIC	51	7
Treatment regimen	TEC	49	5	2.784	0.733
	EC-T	4	1
	TCH	13	2
	EC-TH	26	6
	Replacement single chemotherapy	6	0
	Replacement chemotherapy + H	6	1
Trastuzumab cycle preoperation	0	59	6	11.418	0.044
	2-3	13	1
	4	19	6
	5	0	1
	6	11	1
	8	2	0